NCT03644511View on ClinicalTrials.gov

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

July 18, 2019

Study Completion Date

September 30, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

Prescribed by physician.

DRUG

Sorafenib (Nexavar, BAY43-9006)

Prescribed by physician.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY